Commodity or Strategic Advantage? Rethinking Sterilization to Reduce Risk, Cost, and Time

Sterilization is a consequential step in the medical device manufacturing process, and one that is central to the compliance and regulatory calculus of healthcare OEMs bringing products to market. As the range of sterilization modalities has expanded, however, the decision has moved beyond regulatory fit alone and into the operational domain. The question is no longer limited to whether a method can effectively sterilize a product to standard, but how that process can be executed with greater efficiency, control, and predictability.

Ideally, OEMs would evaluate sterilization early, align it with product and packaging decisions, and work with partners capable of executing within a unified quality environment. As a result, they would be better positioned to reduce handoffs, shorten response times, and maintain continuity.

In practice, however, many sterilization strategies are still shaped by legacy operating models, where sterilization is treated as a separate, downstream service rather than an integrated and dynamic requirement of manufacturing. Understanding how to improve that model begins with a clear view of the sterilization landscape today: what has changed, what has stabilized, and what the direction of travel will likely be for the industry as device manufacturers continue to navigate supply continuity and time-to-market pressures.

The Modality Landscape: Stable, but Still Structurally Complex

Ethylene oxide (EO) remains the dominant sterilization modality for medical devices, particularly for products with complex geometries, electronics, or heat- and moisture-sensitive materials. While regulatory scrutiny around EO has intensified in recent years, particularly in the United States, the near-term outlook for capacity is more stable than many anticipated. The U.S. government has extended compliance timelines and eased immediate pressure on existing facilities, even as emissions management and community impact remain ongoing considerations.

Yet not all EO-capable facilities are the same. Differences in facility design, abatement infrastructure, monitoring capabilities, and overall compliance maturity can materially affect performance and long-term reliability. Facilities that have invested in modern emission controls and purpose-built process architectures are generally better positioned to operate consistently across shifting regulatory conditions. For OEMs, the implication is less about access to EO in the abstract and more about the quality and resilience of the environment in which it is executed. 

Radiation-based modalities, including gamma and X-ray, remain important complements. Gamma is well established and broadly accepted, though dependent on a finite global supply of Cobalt-60. X-ray continues to scale as an alternative that offers comparable penetration without reliance on radioactive sources. Together, these modalities expand the range of viable sterilization strategies, but also introduce new considerations around selection, validation, and long-term flexibility.

The overall sterilization landscape is not defined by a single constraint, but by variation across modalities, providers, and operating models. For OEMs, decisions made late or based on limited options can still introduce unnecessary risk. Those that maintain flexibility, both in modality access and in how sterilization is integrated into their operations, are better positioned to adapt as requirements evolve.

From product launches to M&A and manufacturing trends, the MPO Source delivers the medtech news you need twice a week. Subscribe here!

The Cost of Fragmented Sterilization Models

Many OEMs underestimate how much time and risk are embedded in traditional sterilization workflows. In legacy models, sterilization is performed at third-party facilities, separated from manufacturing and packaging by transportation, staging, and queue time. That structure introduces friction at each handoff and limits visibility once the product leaves the production environment.

For EO, in particular, the process itself is inherently multi-step. Products, having been shipped from the manufacturer to a third-party sterilization vendor, often move through preconditioning rooms before entering the sterilization chamber, followed by separate aeration to remove residual gas. Even after processing is complete, release is frequently delayed by biological indicator incubation, which can impose fixed multi-day holds regardless of cycle performance.

Taken together, these elements can stretch total lead times into weeks. During that time, finished goods inventory accumulates, deviations become more disruptive to manage, and visibility into process conditions can be limited. From a risk perspective, OEMs also assume indirect exposure to their sterilization partner’s facility design, emissions controls, and regulatory posture—factors not always fully visible when sterilization is treated as a transactional service.

Disruptions at sterilization facilities—whether driven by regulatory action, capacity constraints, or operational issues—have led to delayed launches, supply shortages, and the need to qualify alternative pathways under time pressure. OEMs operating with single-source or late-stage sterilization strategies have the least flexibility when those disruptions occur. Fragmented models are more likely to reduce throughput, slow production, and increase operating costs.

Modality Selection: Strategic Trade-Offs

No sterilization modality is universally superior. Each carries advantages and constraints that must align with product design, materials, and supply-chain strategy.

EO remains indispensable for complex devices, electronics, and products incompatible with radiation. However, it is also the most scrutinized modality, with longer cycle times and increasing regulatory burden. Differentiation among EO providers increasingly comes down to the experience and compliance history of the provider as well as facility design, process architecture, and emissions controls.

Gamma irradiation is well established and broadly accepted, offering reliable penetration and relatively rapid release. Its dependency on Cobalt-60, however, introduces long-term supply and pricing uncertainty that OEMs must factor into risk assessments.

X-ray irradiation is gaining momentum as an alternative that delivers gamma-like penetration without reliance on radioactive sources. X-ray also enables pallet-level processing, which can simplify logistics and improve throughput for high-volume programs. Adoption is growing as OEMs seek modality diversification to reduce single-point failures.

Modality decisions made late in development can introduce avoidable constraints requiring redesign, revalidation, or limiting future flexibility. As a result, OEMs are increasingly evaluating sterilization in parallel with product and packaging development to preserve optionality as programs scale.

Why Integration Changes the Equation

The structure of the sterilization partnership matters as much as the modality itself. When sterilization is tightly integrated with manufacturing and packaging, particularly within healthcare-specific environments, OEMs gain meaningful advantages.

Integrated models reduce the number of handoffs between production and final release, removing sources of delay and potential damage. They also maintain continuity within a single quality system that supports simplified audit scope, accelerates deviation responses, and preserves traceability from initial build through sterilized product release.

Just as important, integration allows the sterilization strategy to remain flexible. Access to multiple modalities—EO, gamma, and X-ray—within a consistent operational and quality framework enables decisions to be based on product and program needs rather than the limitations of a fragmented supplier network. It also creates a more practical path to redundancy when requirements shift or capacity constraints emerge.

The advantage is not limited to efficiency gains. Integrated models improve responsiveness, reduce exposure to external disruption, and establish clearer accountability across the full manufacturing and sterilization process—factors that become increasingly important as programs scale and requirements evolve.

Quantifying Impact: Time, Inventory, and Cost

The benefits of sterilization model design are most visible in time, inventory, and cost. Advances in EO system design now allow preconditioning, sterilization, and aeration to occur within a single chamber, eliminating intermediate transfers and significantly reducing cycle time. When combined with validated parametric release, these approaches can remove multi-day biological indicator holds and enable release immediately after processing.

Shorter sterilization lead times translate directly into lower finished goods inventory and reduced working capital requirements. For high-volume or high-value devices, even modest reductions in dwell time can have a meaningful financial impact when applied across a full portfolio. These improvements also support faster response to demand shifts and reduce the likelihood of delays or expedited recovery efforts when timelines compress.

A Practical Framework for Evaluation 

Rather than relying on headline cycle times or capacity claims, OEMs should evaluate sterilization partners against a structured set of criteria:

• Modality strategy: Is there redundancy or a credible roadmap for diversification?
• Process architecture: How are cycle steps configured, and where does time accumulate?
• Release methodology: Is parametric release supported and well established?
• Regulatory resilience: How are emissions, abatement, and community impacts addressed?
• Integration and visibility: How does sterilization connect with manufacturing and quality operations?

The Shift in How Sterilization is Managed

Medical device manufacturers face an increasingly complex macroeconomic environment dictated by a range of factors from tariffs to rising raw material costs. Leading companies across the sector are identifying high-spend areas and performance gaps to preserve margins and maintain the competitiveness of their product portfolios. If it isn’t already, sterilization should be one of the key functions under review as OEMs map their future strategic goals. Sterilization is a central, strategic capability and must be evaluated within the same discipline applied to product lifecycle design, quality, and other manufacturing concerns.

Even as sterilization modality options expand and regulatory conditions continue to evolve, the best path forward is one enabling flexibility, resilience, and, ultimately, control. Securing these advantages starts with rethinking where and how sterilization fits into the operating model today.